HomepageIMMP • NASDAQ
add
Immutep Ltd - ADR
Vorige slotkoers
$Â 1,75
Dag-range
$Â 1,73 - $Â 1,80
Jaar-range
$Â 1,65 - $Â 3,34
Beurswaarde
269,09Â mln. USD
Gem. volume
78,34K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (AUD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,57Â mln. | 49,13% |
Bedrijfskosten | 2,12Â mln. | -11,84% |
Netto inkomsten | -11,19Â mln. | -5,41% |
Netto winstmarge | -710,92 | 29,31% |
Winst per aandeel | — | — |
EBITDA | -13,20Â mln. | -18,90% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (AUD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 159,26Â mln. | 53,53% |
Totale activa | 182,33Â mln. | 47,29% |
Totale passiva | 9,86Â mln. | 21,00% |
Totaal aandelenvermogen | 172,47 mln. | — |
Uitstaande aandelen | 1,46 mld. | — |
Koers-boekwaardeverhouding | 14,58 | — |
Rendement op activa | -18,11% | — |
Rendement op kapitaal | -18,96% | — |
Kasstroom
Nettomutatie in liquide middelen
| (AUD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -11,19Â mln. | -5,41% |
Operationele kasstroom | -14,27Â mln. | -54,72% |
Kasstroom uit beleggingen | -31,41Â mln. | -14.887,41% |
Kasstroom uit financiering | -213,58K | 1,09% |
Nettomutatie in liquide middelen | -43,95Â mln. | -346,60% |
Vrije kasstroom | -8,37Â mln. | -13,11% |
Over
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Opgericht
2001
Website
Werknemers
19
